Cancer du sein in situ

Due to widespread mammography screening since 2004, in situ breast cancers represent 15 to 20% of newly diagnosed breast cancers in France. These guidelines define the best clinical strategies from diagnosis to follow-up of these patients. They have been established by the French National Cancer Institute and the Société française de sénologie et pathologie mammaire. Mammography and ultrasound (US) should be performed during initial investigation. Magnetic resonance imaging has limited indications. When feasible, standard treatment of ductal carcinoma in situ includes lumpectomy and radiotherapy; 2-mm clear margins are required. Axillary dissection is not recommended. Situations when sentinel node biopsy should be performed are described. Clinical guidelines for lobular carcinoma in situ use WHO 2003 LIN classification. Standard follow-up of all treated patients includes at least annual clinical examination and mammography and often US.